GPT Healthcare Q2 FY27 Results: Standalone Net Profit ₹15.40 Crore on Total Income of ₹139 Crore
- Earnings
- Healthcare services
Reviewed byRachit TripathiBlacklitt Research
GPT Healthcare (NSE: GPTHEALTH) reported total income of ₹138.57 crore and net profit of ₹15.40 crore for the quarter ended 30 Sep 2026, standalone, it said in a filing on 05 Nov 2026. The company has no subsidiary, so no consolidated results were filed.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹138.57 crore, up 15.2% YoY and 8.1% QoQ
- Net profit and EPS: ₹15.40 crore, up 45.2% YoY; basic EPS ₹1.88 against ₹1.29 a year earlier
- Interim dividend: ₹1 per share (10% of ₹10 face value), record date 12 Nov 2026
- Finance costs: ₹2.10 crore, down 2.9% YoY and QoQ
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 138.57 | 120.25 | +15.2% | 128.23 | +8.1% | |
| Revenue from operations | 135.62 | 118.91 | +14.1% | 126.20 | +7.5% |
| Other income | 2.94 | 1.34 | +120.0% | 2.03 | +45.3% |
| 15.40 | 10.60 | +45.2% | 12.73 | +21.0% | |
| Profit before tax | 20.68 | 15.07 | +37.2% | 17.16 | +20.5% |
| Finance costs | 2.10 | 2.16 | -2.9% | 2.16 | -2.9% |
| Depreciation | 7.05 | 6.35 | +11.0% | 6.88 | +2.4% |
| Tax expense | 5.27 | 4.46 | +18.1% | 4.43 | +19.0% |
| Net profit margin | 11.12% | 8.82% | +2.30 pp | 9.93% | +1.19 pp |
| EPS, basic (₹) | 1.88 | 1.29 | +45.7% | 1.55 | +21.3% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew faster than income. Net profit rose 45.2% year on year to ₹15.40 crore while total income rose 15.2%, and profit before tax rose 37.2% to ₹20.68 crore. Tax expense rose 18.1% to ₹5.27 crore, so the net margin widened from 8.82% to 11.12%.
Other income of ₹2.94 crore was 2.1% of total income and 14.2% of profit before tax, up 120.0% from ₹1.34 crore a year earlier.
Finance costs of ₹2.10 crore were 1.5% of total income, slightly lower than a year earlier. Depreciation rose 11.0% to ₹7.05 crore. Tax expense was 25.5% of profit before tax in the quarter.
The company operates in one reportable segment, healthcare services in India. The statutory auditors, S.R. Batliboi & Co. LLP, conducted a limited review and issued an unmodified conclusion. The filing does not state the reason for the change in revenue or profit against the year-earlier quarter, and it does not say whether the tax expense includes adjustments for earlier years in the current quarter.
Inference
The company declared an interim dividend of ₹1 per equity share, 10% of the ₹10 face value, with a record date of 12 Nov 2026. Paid-up equity share capital is ₹82.05 crore. Cash flow notes in the filing show dividend payments of ₹12.31 crore in the half year.
Half-year revenue from operations was ₹261.83 crore and profit after tax was ₹28.13 crore. The filing does not say what drove the year-on-year change in quarterly profit, nor the company's plans for the coming quarters.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
